Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imagion Biosystems Ltd. ( (AU:IBX) ) has provided an update.
Imagion Biosystems has provided a business update ahead of its Annual General Meeting, highlighting the progress of its MagSense® HER2 Imaging Agent for HER2+ breast cancer. The company plans to begin manufacturing the imaging agent in June and aims to file an Investigational New Drug application with the FDA for a Phase 2 study in the third quarter of 2025. The company has engaged with the FDA for feedback and identified a Principal Investigator for the study. Additionally, Imagion is optimizing MRI protocols in collaboration with Siemens and Wayne State University. The company is also preparing to restart its prostate and ovarian cancer programs, with Dr. Kayat-Bittencourt joining as a clinical advisor for the prostate cancer program.
More about Imagion Biosystems Ltd.
Imagion Biosystems is a company focused on enhancing healthcare outcomes through the early detection of cancer. It is developing a non-radioactive and precision diagnostic molecular imaging technology that combines biotechnology and nanotechnology to detect cancer and other diseases earlier and with higher specificity.
Average Trading Volume: 451,964
Technical Sentiment Signal: Sell
Current Market Cap: A$2.42M
For a thorough assessment of IBX stock, go to TipRanks’ Stock Analysis page.